BEONE MEDICINES (06160) News

BeiGene (06160.HK): Issued 741,300 shares under the share option plan.

Gelonghui, March 12th - BeiGene (06160.HK) announced that on March 11, 2026, it issued 741,300 ordinary shares under the fifth amended and restated 2018 Employee Stock Option Plan.

Gelonghui Finance07:41

BeOne Medicines Aligns 2025 Results With Dual Hong Kong and U.S. Reporting Rules

TipRanksMar 11 17:40

BEONE MEDICINES: NOTICE OF AUDIT COMMITTEE ACTION

HKEXMar 11 17:32 · Announcements

BeOne Medicines Opens New 2018 Employee Share Purchase Plan Offering Period

TipRanksMar 10 17:16

The biopharmaceutical industry has been positioned as an emerging pillar industry, with the Hang Seng Stock Connect Innovative Pharmaceutical ETF (E Fund) (159316) rising by 3.57%.

Gelonghui, March 10 | The Hong Kong-listed pharmaceutical stocks rose, with Akeso Inc. up more than 9%, 3SBio Inc. up over 6%, and Innovent Bio up over 4%, driving the Hang Seng Innovation Pharmaceutical ETF (159316) managed by E Fund to rise by 3.57%. In terms of news, in this year's government work report, the biopharmaceutical industry was explicitly listed as a 'new pillar industry' at the national level, alongside industries such as integrated circuits, aerospace, and low-altitude economy. This marks the first time that the government work report has proposed the development of the biopharmaceutical industry from the perspective of a pillar industry, sending an important policy signal to accelerate the upgrading of the sector. Dongwu Securities noted that the Two Sessions for the first time designated innovative drugs as

Gelonghui FinanceMar 10 10:42

Two Sessions Set New Course! Analysts Favor These Sectors as Fund Managers Map Out '2026 Investment Blueprint'

During the Two Sessions in 2026, the draft outline of the '15th Five-Year Plan' and the government work report not only provided a clear blueprint for economic development and policy direction but also signaled numerous investment opportunities.

Securities Times ChinaMar 9 08:54

BeOne Medicines Grants New RSUs to 188 Employees Under Incentive Plan

TipRanksMar 6 17:39

Express News | Zheng Shanjie: The output value related to the six major emerging pillar industries—integrated circuits, aerospace, biomedicine, and others—is expected to exceed 10 trillion yuan by 2030.

BreakingsMar 6 16:46

Orient Securities: Short-term volatility in the innovative drug sector may continue. It is recommended to actively seek investment opportunities at lower positions.

Overall, the performance of domestically produced drugs overseas has become a focal point of industry attention.

Zhitong FinanceMar 6 15:15

Hong Kong-listed innovative pharmaceutical companies are leveraging policy support. Institutions: The biopharmaceutical sector is transitioning from an 'R&D investment phase' to a 'value harvest phase.'

① Why has the biopharmaceutical sector recently attracted significant market attention? ② How do institutions view recent policies?

cls.cnMar 6 14:05

Surging BD transactions and policy catalysts! The Hang Seng Medicine ETF (159892) surged by 3.67%, while the HK Connect Healthcare ETF (520510) rose by 2.89%, with its real-time turnover rate ranking first among similar products.

Gelonghui, March 6th | Today, the innovative drug sector rebounded strongly. The constituent stock 3SBio Inc. surged by 10%, driving the Hang Seng Medicine ETF (159892) to rise by 3.67%. The Stock Connect Healthcare ETF (520510) increased by 2.89%, with a turnover rate of 54.58%, ranking first among similar products. In terms of news: ① The 2026 Government Work Report identifies new quality productive forces as a core focus, listing biomedicine alongside integrated circuits, aerospace, and low-altitude economy for the first time, clearly defining it as a national 'emerging pillar industry.' It is expected that innovative drugs will receive more concentrated policy support, funding, and resource allocation. ② Business development (BD) transactions continue.

Gelonghui FinanceMar 6 13:01

The innovative drug sector has rebounded strongly, driven by both policy support and industrial momentum, with the low-cost Hang Seng Stock Connect Innovative Drug ETF (E Fund) (159316) rising over 3%.

Gelonghui March 6th | The Hang Seng Stock Connect Innovative Pharmaceutical ETF (159316), managed by E Fund, surged over 3.9% in the morning session, becoming the top-performing sector-specific ETF during that period. From a news perspective, the industry is experiencing multiple catalysts. Policy catalyst: The government work report has mentioned innovative pharmaceuticals for three consecutive years, and biomedicine has been elevated to an 'emerging pillar industry.' In the 2026 government work report, biomedicine was, for the first time, listed alongside integrated circuits, aerospace, and low-altitude economy, clearly defined as a national 'emerging pillar industry.' With the elevation of strategic positioning, innovative pharmaceuticals are expected to receive more concentrated policy support, funding, and resource allocation. This is further reinforced by the report's proposal to 'launch commercial'

Gelonghui FinanceMar 6 10:55

The BD+ performance catalyst for innovative drugs continues, with the target index of Tianhong Innovative Drug ETF (517380), a unique product in the entire market, rising by over 3%.

Gelonghui, March 6 | Today, the Hong Kong stock pharmaceutical sector rebounded comprehensively. 3SBio Inc. surged over 9%, while Sunshine Guojian Pharmaceutical rose more than 5%, driving the underlying index of Tianhong CSI Innovation Drug ETF (517380) up by over 3%. The Tianhong CSI Innovation Drug ETF (517380) gathers China’s core innovative drug capabilities and represents new quality productivity, covering the entire industrial chain from pre-clinical research to commercialization. It offers a one-stop layout for leading A-share and Hong Kong stock innovative drug companies and Contract Research Organizations (CRO). Leveraging policy support, accelerated R&D, and optimized medical insurance payment systems, it effectively reduces investment uncertainty in individual enterprises while capturing golden development opportunities in the industry through comprehensive industrial chain exposure.

Gelonghui FinanceMar 6 10:31

The concept of innovative pharmaceuticals in Hong Kong stocks has gained momentum, with biomedicine emerging as a 'new pillar industry' for the first time. Both business development (BD) and financial performance are expected to serve as dual drivers.

The innovative drug sector strengthened during early trading. As of press time, 3SBio Inc. surged nearly 9%, Hutchison China MediTech rose over 8%, Innovent Bio climbed nearly 6%, Hengrui Pharma increased more than 5%, and Connaught Medical-B gained 5%.

Zhitong FinanceMar 6 10:22

CICC Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)

TipRanksMar 6 08:26 · Ratings

BeiGene (688235): Q4 revenue in line with expectations; abundant catalysts anticipated in 2026.

Considering that the company's revenue for 4Q25 met expectations, operating profit was slightly better than expected, while net profit fell below expectations due to the drag from non-operating items, we believe the market seems concerned about higher-than-expected R&D expenses in the fourth quarter and revenue guidance for 2026.

SPDB InternationalMar 6 00:00

HK Stock Ratings Summary: CICC Maintains Buy Rating for Beigene

Cailian Press will regularly compile ratings and target prices from various institutions for Hong Kong stocks.

cls.cnMar 5 15:15

BeiGene (688235): Achieves First Annual GAAP Net Profit; Zanubrutinib Continues to Gain Momentum

Event: The company released its key financial data for the full year 2025 and the fourth quarter of 2025. Total revenue for the full year 2025 was $5.343 billion, representing a year-on-year increase of 40%. GAAP net profit and adjusted net profit were respectively...

Tianfeng SecuritiesMar 5 00:00

BeiGene (688235): Performance in Line with Expectations, Abundant Catalysts for the Full Year

The company's 2025 performance is largely in line with our expectations. The company announced its 2025 results: revenue of $5.343 billion, a year-on-year increase of 40%, including product revenue of $5.282 billion, a year-on-year increase of 40%, and GAAP net profit.

CICCMar 4 00:00

Which industries and individual stocks are being more frequently researched by billion-yuan private equity firms such as Gaoyi and Freshwater Springs?

①In February, 383 private equity firms conducted 704 research activities, with large-scale institutions showing strong participation; ②Research focused on sectors such as power equipment, machinery, computers, electronics, and pharmaceuticals and biotechnology; ③Large private equity firms were actively engaged in frequent visits to high-performing industry tracks.

cls.cnMar 3 19:04